RADNOR, Pennsylvania, June 11 / PRNewswire / – New high-purity resin improves bioprocessing processes and brings selection and efficiency to the processes and protocols of monoclonal antibody production
Monoclonal antibody drugs treat a variety of clinical indications. In cancer treatment, monoclonal antibodies use the natural functions of the immune system to fight the disease.
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to life sciences, high technology, and applied materials customers, today announced the launch of a new, recombinant Protein A affinity chromatography resin that is used for purification of antibodies is used during the production of monoclonal antibodies.
The demand for medical care is increasing rapidly in most parts of the world, mainly due to the aging population, the increasing prevalence of chronic diseases and improved access to health care. Monoclonal antibodies are proteins that mimic or strengthen the body’s immune system. Biopharmaceutical manufacturers are looking for ways to optimize the monoclonal antibody production process for increased efficiency, faster time to market and lower costs.
Protein A chromatography is a proven downstream purification step in the production of monoclonal antibodies. However, there is still a need to reduce the overall cost of cleaning while improving purity and yield. Avantor®’s new recombinant Protein A resin solves these challenges.
Dr. Ger Brophy, Executive Vice President for Biopharma Production at Avantor said: “Biopharmaceutical developers and manufacturers are urgently looking for new tools to make the production process more efficient. They cannot compromise on quality standards because they work on the patient to provide safe and efficient high-performance medication in good time. “
In performance tests compared to other premium Protein A resins on the market today, the new recombinant Protein A resin JTBaker® BAKERBOND® PROchievA (TM) from Avantor performs well and is characterized by best-in-class cleaning in critical Protein-A -Affinity chromatography step of producing monoclonal antibodies. Avantor resin is compatible with current manufacturing standards, which ensures workflow continuity and compliance logs.
“Our resin offers customers a first-class, high-performance alternative to existing cleaning technologies, with the advantage of greater flexibility and security in the supply chain,” added Dr. Brophy added.
The BAKERBOND® PROchievA (TM) resin is manufactured at Avantor’s Bridgewater Innovation Center in N.J., USA, and is the company’s latest example of improved bio-processing efficiency in the life science industry. Avantor recently partnered with the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, to address downstream bottleneck bottlenecks in the production of monoclonal antibodies. Avantor recently opened its ninth Biopharma Innovation and Customer Support Center, which is located in Shanghai, China.
The new resin extends Avantor’s J.T.Baker® product family for biopharmaceutical research and production. Avantor’s J.T.Baker® chromatography products enable biopharmaceutical manufacturers to achieve higher production efficiency, meet strict regulatory requirements, and accelerate regulatory approval for new therapies.
For more information on BAKERBOND® PROchievA (TM) resin and other J.T.Baker® chromatography products, visit www2.avantorsciences.com/ProteinA.
For information on Avantor’s biopharmaceutical capabilities in relation to monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies and low molecular weight products, visit www.avantorsciences.com/en/biopharma.html.
About Avantor
Avantor® is a leading global provider of mission-critical products and services to customers in the life sciences, high technology and applied materials. The company operates in more than 30 countries and offers an extensive portfolio of products and services. As our sales brand, VWR offers an integrated, seamless shopping experience that is optimized for the way customers do business. We set science in motion to create a better world. More information is available at www.avantorsciences.com.
Global media contact
Robert Donohoe
Senior Director, Corporate Communications
Avantor
Office: 610-386-6420
Mobile: 484-688-4730
[email protected]
Photo –
https://mma.prnewswire.com/media/1122321/Avantor_Protein_A_PROchievA.
jpg
Logo – https://mma.prnewswire.com/media/718849/avantor_Logo.jpg
– .
